Matinas BioPharma
MTNB
50 hedge funds and large institutions have $21.5M invested in Matinas BioPharma in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 11 closing their positions.
6% more capital invested
Capital invested by funds: $20.3M → $21.5M (+$1.21M)
0.02% more ownership
Funds ownership: 0.23% → 0.25% (+0.02%)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
11% less funds holding
Funds holding: 56 → 50 (-6)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NRS
Neville Rodie & Shaw
New York
|
+$1.32M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$403K |
| 3 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
+$242K |
| 4 |
Jane Street
New York
|
+$112K |
| 5 |
VF
Virtu Financial
New York
|
+$70.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
-$509K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$60.6K |
| 3 |
SCP
Sandhill Capital Partners
Buffalo,
New York
|
-$40K |
| 4 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$26K |
| 5 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IWC
51
Integrated Wealth Concepts
Waltham,
Massachusetts
| – | -$20K | -502 | Closed |
|
|
RJA
52
Raymond James & Associates
St Petersburg,
Florida
| – | -$18K | -440 | Closed |
|
53
Kovitz Investment Group Partners
Chicago,
Illinois
| – | -$12K | -300 | Closed |
|
54
Rafferty Asset Management
New York
| – | -$10K | -257 | Closed |
|
|
AWM
55
AE Wealth Management
Topeka,
Kansas
| – | -$10K | -238 | Closed |
|
|
FC
56
Fore Capital
New York
| – | -$8K | -200 | Closed |
|
57
Fidelity Investments
Boston,
Massachusetts
| – | -$6K | -148 | Closed |
|
|
TRCT
58
Tower Research Capital (TRC)
New York
| – | -$5K | -112 | Closed |
|
|
LSA
59
Lansing Street Advisors
Ambler,
Pennsylvania
| – | -$1K | -15 | Closed |
|
MTNB Hedge Fund Activity: Q2 2022 in Review
50 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2022, worth a combined $21.5M — up 6% from $20.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of MTNB and 5 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Neville Rodie & Shaw, adding an estimated $1.32M. The largest seller was Courage Capital Management, cutting an estimated $509K.
- 50 institutional investors held Matinas BioPharma (MTNB) as of Q2 2022, down from 56 in Q1 2022.
- Funds reported $21.5M of Matinas BioPharma stock for Q2 2022, up 6% quarter-over-quarter.
- 5 funds opened new Matinas BioPharma positions in Q2 2022 and 11 closed out, a net change of -6 holders.
- The largest Matinas BioPharma buyer in Q2 2022 was Neville Rodie & Shaw, an estimated $1.32M added.
- The largest Matinas BioPharma seller in Q2 2022 was Courage Capital Management, an estimated $509K sold.
Based on aggregated 13F filings for Q2 2022.